Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,195 shares of the company’s stock after selling 565 shares during the period. Yousif Capital Management LLC’s holdings in Pacira BioSciences were worth $783,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in PCRX. China Universal Asset Management Co. Ltd. boosted its position in shares of Pacira BioSciences by 96.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock worth $36,000 after purchasing an additional 583 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Pacira BioSciences by 310.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company’s stock worth $61,000 after purchasing an additional 1,514 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Pacira BioSciences by 63.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,481 shares of the company’s stock worth $137,000 after purchasing an additional 1,736 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Pacira BioSciences by 9.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company’s stock worth $157,000 after purchasing an additional 438 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Pacira BioSciences during the 3rd quarter worth $245,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Gary W. Pace sold 1,066 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $27.21 on Monday. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of 33.59 and a beta of 0.77. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average is $28.41 and its two-hundred day moving average is $29.54. Pacira BioSciences, Inc. has a 12-month low of $25.33 and a 12-month high of $44.62.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.71. The company had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. Research analysts expect that Pacira BioSciences, Inc. will post 2.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PCRX shares. JPMorgan Chase & Co. started coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They set an “overweight” rating and a $45.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research report on Thursday, February 8th. Needham & Company LLC reiterated a “buy” rating and issued a $45.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 9th. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research report on Monday, March 4th. Finally, Royal Bank of Canada decreased their price objective on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $49.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.